Tag Archives: myocardial revascularisation

Introduction Contemporary cardiology guidelines often recommend that decision making should take place by discussions within a multi-disciplinary heart team (HT), particularly in complex patients.1,2 However, very little data exist about the effectiveness of such an approach, about the extent to which HT decisions are implemented, or about the outcome of patients being managed according to decisions made by the HT. We set out to analyse the decisions of our revascularisation HT in a medium-sized regional tertiary centre, in order to optimise our processes, and also to explore the extent to which the HT decisions were actually carried out. Me

European Society of Cardiology congress 2018, held in Munich Other news from the European Society of Cardiology Congress 2018 Not all HDL cholesterol is cardioprotective COMMANDER HF: rivaroxaban in heart failure… …and in VTE in the MARINER trial Is it safe for women with heart disease to become pregnant? Several new guidelines from the ESC were announced at the meeting: ESC guidelines on the management of cardiovascular diseases during pregnancy, first published in 2011, have been updated with a second edition in 2018 2018 ESC/EACTS (European Association for Cardio-Thoracic Surgery) guidelines on myocardial revascularisation 2018 ES

Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. SHIFT: ivabradine shows benefit in heart failure